KalVista Pharmaceuticals, Inc.

PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transac.

businesswire.com - 2026-06-11 08:41:00

KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-06-04 13:01:16

This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance.

fool.com - 2026-05-31 11:48:43

[url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged

gurufocus.com - 2026-05-28 08:00:00

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currentl.

businesswire.com - 2026-05-28 07:00:00

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

gurufocus.com - 2026-05-19 15:00:00

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ.

businesswire.com - 2026-05-19 14:11:00

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

businesswire.com - 2026-05-01 12:30:00

On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.

fool.com - 2026-04-29 17:47:49

MILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Chiesi Group. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-04-29 12:17:00

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

globenewswire.com - 2026-04-29 11:01:31

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating KalVista Pharmaceuticals, Inc. (NASDAQ:  KALV ) related to its sale to Chiesi Group. Under the terms of the proposed transaction, KalVista shareholders are expected to receive $27.00 per share in cash. Is it a fair deal?

globenewswire.com - 2026-04-29 11:01:00

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) to Chiesi Group for $27.00 per share in cash. Halper Sadeh encourages KalVista shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether KalVista and its board of directors.

businesswire.com - 2026-04-29 10:17:00

Italy's ​Chiesi has ‌agreed to ​buy ​KalVista Pharmaceuticals ⁠for ​about $1.9 billion, the ​company said on ​Wednesday, ​as it ‌looks ⁠to grow its ​rare ​disease ⁠drug portfolio.

reuters.com - 2026-04-29 07:53:21

PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi's and KalVista's Boards of Directors and is expected to close in Q3 2026, subject to.

businesswire.com - 2026-04-29 07:42:00

Italian pharma company Chiesi Group will buy U.S.-listed KalVista Pharmaceuticals in an all-cash deal valued ​at about $1.9 billion, the two companies said in ‌a joint statement on Wednesday.

reuters.com - 2026-04-29 07:11:20

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Paul Audhya sold 2,686 shares of the company's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $20.22, for a total value of $54,310.92. Following the completion of the transaction, the insider owned 142,547 shares in the company,

defenseworld.net - 2026-04-21 05:26:44

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Nicole Sweeny sold 1,862 shares of the firm's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the sale, the insider directly owned 51,391 shares of the company's stock, valued

defenseworld.net - 2026-04-21 05:26:43

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) CFO Brian Piekos sold 1,862 shares of the business's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64. Following the transaction, the chief financial officer directly owned 18,150 shares in the company,

defenseworld.net - 2026-04-21 05:26:42

KalVista Pharmaceuticals (NASDAQ: KALV) CEO Ben Palleiko told investors at Needham and Company's 25th Annual Healthcare Conference that the company has seen a strong early commercial launch for EKTERLY, which he described as the "first and only oral on-demand therapy for treatment of HAE attacks." Palleiko said the company launched EKTERLY immediately after FDA approval last

defenseworld.net - 2026-04-18 01:05:11